Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Ian Neeland

Cardiovascular Disease Cleveland, OH Medical Doctor

NPI 1285818740 CMS profile 1279744

11100 Euclid Ave, Cleveland, OH 44106

Open in the dashboard

General payments

$329,260

280 records reported · program years 2020–2025

Research payments

$3,950

Paid to them · 4 records reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$228,565 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Ian Neeland of Cleveland, OH is reported in the CMS Open Payments database as having received $329,260 across 280 general payments and $3,950 in research payments paid to them. Separately, studies naming them as principal investigator received $228,565 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $125,407 76
2024 General $61,488 47
2023 General $76,153 87
2022 General $61,151 59
2022 Research $1,720 2
2021 General $3,021 8
2021 Research $2,230 2
2020 General $2,041 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ian Neeland
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Ian Neeland were reported at $125,407. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Ian Neeland Cardiovascular Disease median Middle half National median
2019 $0 $450 $127–$1,392 $163
2020 $2,041 $242 $77–$751 $114
2021 $3,021 $335 $101–$1,037 $132
2022 $61,151 $395 $121–$1,211 $149
2023 $76,153 $443 $136–$1,283 $160
2024 $61,488 $450 $136–$1,323 $164
2025 $125,407 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $161,249 106 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $110,020 92 payments
  3. Lilly USA, LLC $26,654 27 payments
  4. Novo Nordisk Inc $12,072 13 payments
  5. Eli Lilly and Company $11,881 12 payments
  6. Nestle HealthCare Nutrition Inc. $4,461 1 payment
  7. Merck Sharp & Dohme Corporation $2,016 2 payments
  8. Boehringer Ingelheim International GmbH $183 1 payment
  9. Boston Scientific Corporation $164 2 payments
  10. Novartis Pharmaceuticals Corporation $148 8 payments
  11. Other $411 16 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $231,100 113 payments
  2. Consulting Fee $61,471 16 payments
  3. Travel and Lodging $32,783 51 payments
  4. Food and Beverage $3,848 96 payments
  5. Education $59 4 payments
Products named General payments · program years 2020–2025
  1. Kerendia $161,249 106 payments
  2. JARDIANCE Diabetes $50,507 52 payments
  3. JARDIANCE Diabetes $37,640 28 payments
  4. JARDIANCE Diabetes $26,625 24 payments
  5. MOUNJARO $2,529 3 payments
  6. ZEPBOUND $1,000 1 payment
  7. GENERAL - THERAPIES $138 1 payment
  8. LEQVIO $135 7 payments
  9. CEREZYME $129 1 payment
  10. CERDELGA $129 1 payment
  11. Other $618 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2020–2025
  1. Pfizer Inc. $3,950 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

2,071

Median for Cardiology: 2,533

Drug cost

$971,075

Median for Cardiology: $485,213

Branded share of claims

47.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 199 $234,338
Ozempic Semaglutide Brand 131 $168,830
Kerendia Finerenone Brand 90 $112,691
Mounjaro Tirzepatide Brand 86 $107,858
Trulicity Dulaglutide Brand 72 $74,659
Repatha Sureclick Evolocumab Brand 66 $58,696
Eliquis Apixaban Brand 45 $54,372
Synjardy Xr Empagliflozin/Metformin Hcl Brand 45 $47,541
Farxiga Dapagliflozin Propanediol Brand 20 $26,938
Vascepa Icosapent Ethyl Brand 35 $25,960

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$26,714

Medicare's payments for the services billed

Medicare patients

308

Average age 73

Services billed

541

159 women, 149 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 51%
Arthritis 47%
Diabetes 43%
Chronic kidney disease 39%
Heart failure 34%
Atrial fibrillation 31%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $32,139
$32,139 90 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $22,813
  • Eli Lilly and Company $2,000
  • Lilly USA, LLC $1,750
$26,563 199 —
MOUNJARO
  • Lilly USA, LLC $2,500
$2,500 86 —
CEREZYME
  • GENZYME CORPORATION $64
$64 — —
CERDELGA
  • GENZYME CORPORATION $64
$64 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

284 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record